“Global Attention Deficit Hyperactivity Disorder Drugs Market is estimated to reach $17bn by 2024” says Visiongain report

31 October 2019
Pharma

Visiongain has launched a new pharma report Attention Deficit Hyperactivity Disorder Drugs Market: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.

The global attention deficit hyperactivity disorder is anticipated to witness strong growth during the forecast period. Factors such as the growing prevalence of the ADHD cases in adults and children, growing awareness coupled with support from the government as well as rising regulatory approvals will drive market growth.

The lead analyst of the report commented "The global attention deficit disorder market is one that is driven by innovation. This is vital for maintaining the rich pipeline of ADHD drugs seen in the market today. There is increasing focus to identify and treat ADHD that currently are undertreated and try to serve these neglected markets. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market. This prevents stagnation within the market and will help drive the growth of attention deficit disorder market."

Leading companies featured in the report include Eli Lilly, Johnson and Johnson, Lupin Limited, Mallinckrodt & Co., Neos Therapeutics, Pfizer Inc., Purdue Pharma L.P., Takeda Pharmaceuticals and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

Read

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever